Remarkable inhibition of mTOR signaling by the combination of rapamycin and 1,4-phenylenebis(methylene)selenocyanate in human prostate cancer cells

International Journal of Cancer

Volumn 131, Issue 9, 2012, Pages 2134-2142

  Facompre, Nicole D ^a,c   Sinha, Indu ^a   El Bayoumy, Karam ^a   Pinto, John T ^b   Sinha, Raghu ^a  

^a PENN STATE CANCER INSTITUTE   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

^c WISTAR INSTITUTE   (United States)

Author keywords

combination therapy; mTOR; prostate cancer; selenium

Indexed keywords

1,4 PHENYLENEBIS(METHYLENE)SELENOCYANATE; ANDROGEN; BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; ORGANOSELENIUM DERIVATIVE; PROTEIN KINASE B; PROTEIN KINASE C ALPHA; RAPAMYCIN; RICTOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER INHIBITION; CELL STRAIN; CELL STRAIN C4 2; CELL STRAIN DU145; CELL STRAIN LNCAP; CELL VIABILITY; CONTROLLED STUDY; DOWNSTREAM PROCESSING; DRUG EFFICACY; DRUG STRUCTURE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS INHIBITION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARRIER PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MALE; ORGANOSELENIUM COMPOUNDS; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84865563003     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27468     Document Type: Article

References (40)

1. Wu Y, Chhipa RR, Cheng J, Zhang H, Mohler JL, Ip C,. Androgen receptor-mTOR crosstalk is regulated by testosterone availability: implication for prostate cancer cell survival. Anticancer Res 2010; 30: 3895-901.
2. Wang X, Proud CG,. The mTOR pathway in the control of protein synthesis. Physiology 2006; 21: 362-9. (Pubitemid 44511764)
3. Gibbons JJ, Abraham RT, Yu K,. Mammalian target of rapamycin reveals a signaling pathway important for normal and cancer cell growth. Semin Oncol 2009; 36: S3-S17.
4. Kremer CL, Klein RR, Mendelson J, Browne W, Samadzedeh LK, Vanpatten K, Highstrom L, Pestano GA, Nagle RB,. Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate 2006; 66: 1203-12. (Pubitemid 44175342)
5. Brown RE, Zotalis G, Zhang PL, Zhao B,. Morphometric confirmation of a constitutively activated mTOR pathway in high grade prostatic intraepithelial neoplasia and prostate cancer. Int J Clin Exp Pathol 2008; 1: 333-42.
6. Dai B, Kong YY, Ye DW, Ma CG, Zhou X, Yao XD,. Activation of the mammalian target of rapamycin signaling pathway in prostate cancer and its association with patient clinicopathological characteristics. BJU Int 2009; 104: 1009-16.
7. Sarbassov DD, Guertin DA, Ali AM, Sabatini DM,. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307: 1098-101. (Pubitemid 40262113)
8. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM,. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004; 14: 1296-302. (Pubitemid 38991819)
9. Jozwiak J, Jozwiak S, Oldak M,. Molecular activity of sirolimus and its possible application in tuberous sclerosis treatment. Med Res Rev 2005; 26: 160-80.
10. Lane HA, Breuleux M,. Optimal targeting of the mTORC1 kinase in human cancer. Curr Opin Cell Biol 2009; 21: 219-29.
11. Wang Y, Mikhailova M, Bose S, Pan CX, deVere White RW, Ghosh PM,. Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival. Oncogene 2008; 27: 7106-17.
12. Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H, Sun Y, Ouyang X, Gerald WL, Cordon-Cardo C, Abate-Shen C,. Targeting Akt/mTOR and ERK MAPK signaling inhibits hormone refractory prostate cancer in a preclinical mouse model. J Clin Invest 2008; 118: 3051-64.
13. Schayowitz A, Sabnis G, Njar VC, Brodie AM,. Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro. Mol Cancer Ther 2008; 7: 121-32.
14. Liu QJ, Xu XH, Shang DH, Tian Y, Lü WC, Zhang YH,. Rapamycin enhances the susceptibility of both androgen-dependent and -independent prostate carcinoma cells to docetaxel. Chin Med J 2010; 123: 356-60.
15. Zhang W, Zhu J, Efferson CL, Ware C, Tammam J, Angagaw M, Bettano KA, Kasibhatla S, Reilly JF, Sur C, Majumder PK,. Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancer. Cancer Res 2009; 69: 7466-72.
16. Facompre ND, El-Bayoumy K,. Potential stages for prostate cancer prevention with selenium: implications for cancer survivors. Cancer Res 2009; 69: 2699-703.
17. Desai D, Sinha I, Null K, Wolter W, Suckow MA, King T, Amin S, Sinha R,. Synthesis and anti-tumor properties of selenocoxib-1 against rat prostate adenocarcinoma cells. Int J Cancer 2010; 127: 230-8.
18. Pinto JT, Lee J-I, Sinha R, MacEwan M, Cooper AJL,. Chemopreventive mechanisms of α-keto acid metabolites of naturally occurring organoselenium compounds. Amino Acids 2011; 41: 29-41.
19. Sinha I, Null K, Walter W, Suckow MA, King T, Pinto JT, Sinha R,. Methylseleninic acid down regulates hypoxia inducible factor-1α in invasive prostate cancer. Int J Cancer 2012; 130: 1430-39.
20. Facompre ND, El-Bayoumy K, Sun YW, Pinto J, Sinha R,. 1,4-phenylenebis(methylene) selenocyanate (p-XSC) but not selenomethionine inhibits androgen receptor and Akt signaling in human prostate cancer cells. Cancer Prev Res 2010; 3: 975-84.
21. Hu H, Jiang C, Ip C, Rustum YM, Lü J,. Methylseleninic acid potentiates apoptosis induced by chemotherapeutic drugs in androgen-independent prostate cancer cells. Clin Cancer Res 2005; 11: 2379-88. (Pubitemid 40490199)
22. Zhao R, Xiang N, Domann FE, Zhong W,. Effects of selenite and genistein on G2/M cell cycle arrest and apoptosis in human prostate cancer cells. Nutr Cancer 2009; 613: 397-407.
23. Vadgama JV, Wu Y, Shen D, Hsia S, Block J,. Effect of selenium in combination with Adriamycin or Taxol on several different cancer cells. Anticancer Res 2000; 20: 1391-414. (Pubitemid 30628143)
24. Yamaguchi K, Uzzo RG, Pimkina J, Makhov P, Golovine K, Crispen P, Kolenko VM,. Methylseleninic acid sensitizes prostate cancer cells to TRAIL-mediated apoptosis. Oncogene 2005; 24: 5868-77. (Pubitemid 43080078)
25. El-Bayoumy K, Chae YH, Upadhyaya P, Meschter C, Cohen LA, Reddy BS,. Inhibition of 7,12-dimethylbenz(a)anthracene-induced tumors and DNA adduct formation in the mammary glands of female Sprague-Dawley rats by the synthetic organoselenium compound 1,4-phenylenebis(methylene)selenocyanate. Cancer Res 1992; 52: 2402-7.
26. Pinto JT, Sinha R, Papp K, Facompre ND, Desai D, El-Bayoumy K,. Differential effects of naturally occurring and synthetic organoselenium compounds on biomarkers in androgen responsive and androgen independent human prostate carcinoma cells. Int J Cancer 2007; 120: 1410-7. (Pubitemid 46355374)
27. Sinha R, Pinto JT, Facompre N, Kilheffer J, Baatz JE, El-Bayoumy K,. Effects of naturally occurring and synthetic organoselenium compounds on protein profiling in androgen responsive and androgen independent human prostate cancer cells. Nutr Cancer 2008; 60: 267-75. (Pubitemid 351451281)
28. Johnston LJ, Brown J, Shizuru JA, Stockerl-Goldstein KE, Stuart MJ, Blume KG, Negrin RS, Chao NJ,. Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. Biol Blood Marrow Transpl 2005; 11: 47-55. (Pubitemid 40057993)
29. Chou TC, Talalay P,. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
30. Chou TC,. Preclinical versus clinical drug combination studies. Leuk Lymph 2008; 49: 2059-80.
31. Chou TC,. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010; 70: 440-6.
32. 2481 is a marker for intact mTOR signaling complex 2. Cancer Res 2009; 69: 1821-7.
33. Soliman GA, Acosta-Jaquez, Dunlop EA, Ekim B, Maj NE, Tee AR, Fingar DC,. mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action. J Biol Chem 2010; 285; 7866-79.
34. Lee YK, Park SY, Kim YM, Kim DC, Lee WS, Surh YJ, Park OJ,. Suppression of mTOR via Akt dependent and independent mechanisms in selenium treated colon cancer cells: involvement of AMPKα1. Carcinogenesis 2010; 31: 1092-99.
35. Abdulah R, Faried A, Kobayashi K, Yamazaki C, Suradji EW, Ito K, Suzuki K, Murakami M, Kuwano H, Koyama H,. Selenium enrichment of broccoli sprout extract increases chemosensitivity and apoptosis of LNCaP prostate cancer cells. BMC Cancer 2009; 9: 414.
36. Guertin DA, Stevens DM, Saitoh M, Kinkel S, Crosby K, Sheen JH, Mullholland DJ, Magnuson MA, Wu H, Sabatini DM,. mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 2009; 15: 148-50.
37. Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman JG, Jen J, Isaacs WB, Bova GS, Sidransky D,. Frequent inactivation of PTEN/MMAC in primary prostate cancer. Cancer Res 1997; 59: 4997-5000. (Pubitemid 27498107)
38. Whang YE, Wu X, Suzuki H, Reiter RE, Tran C, Vessella RL, Said JW, Isaacs WB, Sawyers CL,. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci USA 1998; 95: 5246-50. (Pubitemid 28208583)
39. Lee N, Woodrum CL, Nobil AM, Rauktys AE, Messina MP, Dabora SL,. Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models. BMC Pharmacol 2009; 9: 8-22.
40. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ,. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007; 26: 1932-40. (Pubitemid 46474636)